We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.94B
AUM Growth
+$582M
Cap. Flow
+$429M
Cap. Flow %
10.9%
Top 10 Hldgs %
57.23%
Holding
59
New
11
Increased
8
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$126M
2
IPSC icon
Century Therapeutics
IPSC
+$81.4M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$69.6M
4
AMRS
Amyris Inc.
AMRS
+$44.7M
5
ME
23andMe Holding Co
ME
+$28.5M

Top Sells

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$22.8M
2
ADVM
Adverum Biotechnologies
ADVM
+$21.8M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$16.7M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$11.7M
5
DYN icon
Dyne Therapeutics
DYN
+$9.47M

Sector Composition

Rank Sector Weight
1 Healthcare 88.3%
2 Materials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.83B
$4.04M 0.1%
120,000
– –
FHTX icon
52
Foghorn Therapeutics
FHTX
$271M
$2.31M 0.06%
216,216
– –
ZY
53
DELISTED
Zymergen Inc. Common Stock
ZY
$1.2M 0.03%
+30,000
New +$1.18M
SANA icon
54
Sana Biotechnology
SANA
$868M
$1.18M 0.03%
60,000
– –
ADVM
55
DELISTED
Adverum Biotechnologies
ADVM
– –
-221,162
Closed -$21.8M
BNR
56
Burning Rock Biotech
BNR
$95M
– –
-84,715
Closed -$22.8M
DYN icon
57
Dyne Therapeutics
DYN
$4.69B
– –
-610,000
Closed -$9.47M
TSHA icon
58
Taysha Gene Therapies
TSHA
$1.69B
– –
-820,440
Closed -$16.7M
CDAK
59
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-76,688
Closed -$1.16M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Casdin Capital held 59 positions worth $3.94B, up 17% from $3.36B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Casdin Capital deployed $429M of net new capital in Q2 2021, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Verve Therapeutics: 3,038,167 shares worth $183M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $11.7M trimmed.

  • Casdin Capital's largest Q2 2021 buy was Verve Therapeutics: 3,038,167 shares worth $183M.
  • Casdin Capital added most to Sarepta Therapeutics in Q2 2021, an estimated $25.4M increase.
  • Casdin Capital's biggest Q2 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $11.7M.
  • Casdin Capital fully exited Burning Rock Biotech in Q2 2021, selling an estimated $22.8M.
  • Casdin Capital's ten largest holdings make up 57% of its $3.94B portfolio in Q2 2021.
  • Casdin Capital opened 11 new positions and closed 5 in Q2 2021.
  • Casdin Capital's portfolio value rose 17% quarter-over-quarter to $3.94B.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.